Market closed

Vericel/$VCEL

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Vericel

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Ticker

$VCEL

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

Website

vcel.com

Vericel Metrics

BasicAdvanced

$2.9B

813.59 $0.07

1.67 -

Price and volume

Market cap

$2.9B

Beta

1.67

52-week high

$60.13

52-week low

$37.35

Average daily volume

350K

Financial strength

Current ratio

4.608

Quick ratio

3.633

Long term debt to equity

35.477

Total debt to equity

37.854

Interest coverage (TTM)

-2.00%

Management effectiveness

Return on assets (TTM)

-0.22%

Return on equity (TTM)

1.54%

Valuation

Price to earnings (TTM)

813.592

Price to revenue (TTM)

12.725

Price to book

11.41

Price to tangible book (TTM)

11.7

Price to free cash flow (TTM)

-240.249

Growth

Revenue change (TTM)

22.48%

Earnings per share change (TTM)

-133.92%

3-year revenue growth (CAGR)

13.82%

3-year earnings per share growth (CAGR)

150.97%

What the Analysts think about Vericel

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Vericel stock.

Vericel Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Vericel Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Vericel News

AllArticlesVideos

Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets

GlobeNewsWire·8 hours ago

Vericel Corporation: Hard To Justify Current Valuation

Seeking Alpha·4 weeks ago

Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.

Investors Business Daily·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VCEL

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Vericel stock?

Vericel (VCEL) has a market cap of $2.9B as of January 15, 2025.

What is the P/E ratio for Vericel stock?

The price to earnings (P/E) ratio for Vericel (VCEL) stock is 813.59 as of January 15, 2025.

Does Vericel stock pay dividends?

No, Vericel (VCEL) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Vericel dividend payment date?

Vericel (VCEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Vericel?

Vericel (VCEL) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.